Psychotic bipolar disorders: Dimensionally similar to or categorically different from schizophrenia?

Journal of Psychiatric Research

Volumn 38, Issue 1, 2004, Pages 47-61

  Ketter, Terence A ^a   Wang, Po W ^a   Becker, Olga V ^a   Nowakowska, Cecylia ^a   Yang, Yen Shou ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsants; Antipsychotics; Bipolar disorders; Carbamazepine; Lithium; Mood stabilizers; Psychosis; Schizophrenia; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; HOMOVANILLIC ACID; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AFFECTIVE PSYCHOSIS; AKATHISIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; CARDIOTOXICITY; CONFERENCE PAPER; DELUSION; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYMPTOM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HALLUCINATION; HERITABILITY; HUMAN; INCREASED APPETITE; MAJOR DEPRESSION; MANIA; MOOD DISORDER; NAUSEA; NERVOUSNESS; NEUROBIOLOGY; NEUROIMAGING; NEUROTRANSMISSION; PAIN; PHENOMENOLOGY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RECEPTOR BLOCKING; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; THOUGHT DISORDER; WEIGHT GAIN; XEROSTOMIA;

EID: 0347511639     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(03)00099-2     Document Type: Conference Paper

References (201)

1. Abrams R., Taylor M.A. Importance of schizophrenic symptoms in the diagnosis of mania. American Journal of Psychiatry. 138:1981;658-661.
2. Abrams R., Taylor M.A. The genetics of schizophrenia: a reassessment using modern criteria. American Journal of Psychiatry. 140:1983;171-175.
3. Ahlfors U.G., Baastrup P.C., Dencker S.J., Elgen K., Lingjaerde O., Pedersen V.et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatrica Scandinavica. 64:1981;226-237.
4. Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Keller M.et al. Switching from 'unipolar' to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. Archives of General Psychiatry. 52:1995;114-123.
5. Altshuler L.L., Bartzokis G., Grieder T., Curran J., Mintz J. Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: an MRI study demonstrating neuroanatomic specificity [letter]. Archives of General Psychiatry. 55:1998;663-664.
6. Diagnostic and statistical manual of mental disorders. 4th ed:1994;American Psychiatric Association, Washington.
7. Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry. 159:2002;1-50.
8. Amin F., Silverman J.M., Siever L.J., Smith C.J., Knott P.J., Davis K.L. Genetic antecedents of dopamine dysfunction in schizophrenia. Biological Psychiatry. 45:1999;1143-1150.
9. Andreasen N.C. Thought, language, and communication disorders. I. Clinical assessment, definition of terms, and evaluation of their reliability. Archives of General Psychiatry. 36:1979;1315-1321.
10. Andreasen N.C. Thought, language, and communication disorders. II. Diagnostic significance. Archives of General Psychiatry. 36:1979;1325-1330.
11. Angst J., Frey R., Lohmeyer B., Zerbin-Rudin E. Bipolar manic-depressive psychoses: results of a genetic investigation. Human Genetics. 55:1980;237-254.
12. Asberg M., Bertilsson L., Martensson B., Scalia-Tomba G.P., Thoren P., Traskman-Bendz L. CSF monoamine metabolites in melancholia. Acta Psychiatrica Scandinavica. 69:1984;201-219.
13. Ashcroft G., Dow R., Yates C. Significance of lumbar CSF metabolite measurements in affective illness. Tuomisto J., Paasonen M. CNS and Behavioral Pharmacology. 1976;277-284 University of Helsinki, Helsinki.
14. Atre-Vaidya N., Taylor M.A. Effectiveness of lithium in schizophrenia: do we really have an answer? Journal of Clinical Psychiatry. 50:1989;170-173.
15. Banki C.M. Correlation between cerebrospinal fluid amine metabolites and psychomotor activity in affective disorders. Journal of Neurochemistry. 28:1977;255-257.
16. Baron M., Gruen R., Asnis L., Kane J. Schizoaffective illness, schizophrenia and affective disorders: morbidity risk and genetic transmission. Acta Psychiatrica Scandinavica. 65:1982;253-262.
17. Baron M., Gruen R., Kane J., Asnis L. Modern research criteria and the genetics of schizophrenia. American Journal of Psychiatry. 142:1985;697-701.
18. Benabarre A., Vieta E., Colom F., Martinez-Aran A., Reinares M., Gasto C. Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. European Psychiatry. 16:2001;167-172.
19. Benazzi F. Psychotic versus nonpsychotic bipolar outpatient depression. European Psychiatry. 14:1999;458-461.
20. Berman K.F., Doran A.R., Pickar D., Weinberger D.R. Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. British Journal of Psychiatry. 162:1993;183-192.
21. Berrettini W.H. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biological Psychiatry. 48:2000;531-538.
22. Berrettini W.H. Molecular linkage studies of bipolar disorders. Bipolar Disorders. 3:2001;276-283.
23. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T.et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. American Journal of Psychiatry. 153:1996;1554-1563.
24. Bhrolchain M.N., Brown G.W., Harris T.O. Psychotic and neurotic depression: 2. Clinical characteristics. British Journal of Psychiatry. 134:1979;94-107.
25. Black D.W., Nasrallah A. Hallucinations and delusions in 1,715 patients with unipolar and bipolar affective disorders. Psychopathology. 22:1989;28-34.
26. Bleuler E. Dementia praecox oder gruppe der schizophrenien [Dementia praecox or the group of schizophrenias]. Aschaffenburg G. Handbuch der Psychiatrie Spezieller Teil, 4. Abteilung, 1. 1911;Franz Deuticke, Hälfte, Leipzig.
27. Bowden C.L. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology. 19:1998;194-199.
28. Brockington I.F., Kendell R.E., Wainwright S., Hillier V.F., Walker J. The distinction between the affective psychoses and schizophrenia. British Journal of Psychiatry. 135:1979;243-248.
29. Brodie H., Sach R., Seiver L. Clinical studies of L-5-hydroxytryptophan. Barchas J., Usdin E. Serotonin and Behavior. 1973;549-559 Academic Press, New York.
30. Brown A.S., van Os J., Driessens C., Hoek H.W., Susser E.S. Further evidence of relation between prenatal famine and major affective disorder. American Journal of Psychiatry. 157:2000;190-195.
31. Calabrese J.R., Rapport D.J. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. Journal of Clinical Psychiatry. 60:1999;5-13.
32. Cardno A.G., Marshall E.J., Coid B., Macdonald A.M., Ribchester T.R., Davies N.J.et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Archives of General Psychiatry. 56:1999;162-168.
33. Cardno A.G., Rijsdijk F.V., Sham P.C., Murray R.M., McGuffin P. A twin study of genetic relationships between psychotic symptoms. American Journal of Psychiatry. 159:2002;539-545.
34. Carlson G., Strober M. Affective disorders in adolescence. Psychiatric Clinics of North America. 2:1979;28-34.
35. Carlson G.A., Goodwin F.K. The stages of mania. A longitudinal analysis of the manic episode. Archives of General Psychiatry. 28:1973;221-228.
36. Carpenter W.T. Jr., Strauss J.S., Muleh S. Are there pathognomonic symptoms in schizophrenia? An empiric investigation of Schneider's first-rank symptoms. Archives of General Psychiatry. 28:1973;847-852.
37. Casey D.E., Daniel D.G., Wassef A.A., Tracy K.A., Wozniak P., Sommerville K.W. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 28:2003;182-192.
38. Citrome L., Levine J., Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services. 51:2000;634-638.
39. Cloninger C.R., Martin R.L., Guze S.B., Clayton P.J. Diagnosis and prognosis in schizophrenia. Archives of General Psychiatry. 42:1985;15-25.
40. Coryell W., Keller M., Lavori P., Endicott J. Affective syndromes, psychotic features, and prognosis. II. Mania. Archives of General Psychiatry. 47:1990;658-662.
41. Coryell W., Lavori P., Endicott J., Keller M., VanEerdewegh M. Outcome in schizoaffective, psychotic, and nonpsychotic depression. Course during a six- to 24-month follow-up. Archives of General Psychiatry. 41:1984;787-791.
42. Coryell W., Zimmerman M. The heritability of schizophrenia and schizoaffective disorder. A family study. Archives of General Psychiatry. 45:1988;323-327.
43. Crow T.J. The continuum of psychosis and its implication for the structure of the gene. British Journal of Psychiatry. 149:1986;419-429.
44. Crow T.J. The continuum of psychosis and its genetic origins. The sixty-fifth Maudsley lecture. British Journal of Psychiatry. 156:1990;788-797.
45. Curtis V.A., Dixon T.A., Morris R.G., Bullmore E.T., Brammer M.J., Williams S.C.et al. Differential frontal activation in schizophrenia and bipolar illness during verbal fluency. Journal of Affective Disorders. 66:2001;111-121.
46. Curtis V.A., van Os J., Murray R.M. The Kraepelinian dichotomy: evidence from developmental and neuroimaging studies. Journal of Neuropsychiatry and Clinical Neurosciences. 12:2000;398-405.
47. Dalby J.T., Morgan D., Lee M.L. Schizophrenia and mania in identical twin brothers. Journal of Nervous and Mental Disease. 174:1986;304-308.
48. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry. 148:1991;1474-1486.
49. Delbello M.P., Schwiers M.L., Rosenberg H.L., Strakowski S.M. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry. 41:2002;1216-1223.
50. Dell'Osso L., Akiskal H.S., Freer P., Barberi M., Placidi G.F., Cassano G.B. Psychotic and nonpsychotic bipolar mixed states: comparisons with manic and schizoaffective disorders. European Archives of Psychiatry and Clinical Neuroscience. 243:1993;75-81.
51. Detera-Wadleigh S.D., Badner J.A., Berrettini W.H., Yoshikawa T., Goldin L.R., Turner G.et al. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proceedings of the National Academy of Sciences of the United States of America. 96:1999;5604-5609.
52. Dilsaver S.C., Chen Y.W., Swann A.C., Shoaib A.M., Tsai-Dilsaver Y., Krajewski K.J. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Research. 73:1997;47-56.
53. Dolan R.J., Bench C.J., Liddle P.F., Friston K.J., Frith C.D., Grasby P.M.et al. Dorsolateral prefrontal cortex dysfunction in the major psychoses; symptom or disease specificity? Journal of Neurology, Neurosurgery and Psychiatry. 56:1993;1290-1294.
54. Done D.J., Johnstone E.C., Frith C.D., Golding J., Shepherd P.M., Crow T.J. Complications of pregnancy and delivery in relation to psychosis in adult life: data from the British perinatal mortality survey sample. British Medical Journal. 302:1991;1576-1580.
55. Elkis H., Friedman L., Wise A., Meltzer H.Y. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Archives of General Psychiatry. 52:1995;735-746.
56. Emrich H.M. Studies with (Trileptal) oxcarbazepine in acute mania. International Clinical Psychopharmacology. 5:1990;83-88.
57. Farmer A.E., McGuffin P., Gottesman I.I. Twin concordance for DSM-III schizophrenia. Scrutinizing the validity of the definition. Archives of General Psychiatry. 44:1987;634-641.
58. Fein S., McGrath M.G. Problems in diagnosing bipolar disorder in catatonic patients. Journal of Clinical Psychiatry. 51:1990;203-205.
59. Fennig S., Bromet E.J., Galambos N., Putnam K. Diagnosis and six-month stability of negative symptoms in psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience. 246:1996;63-70.
60. Fennig S., Bromet E.J., Karant M.T., Ram R., Jandorf L. Mood-congruent versus mood-incongruent psychotic symptoms in first-admission patients with affective disorder. Journal of Affective Disorders. 37:1996;23-29.
61. Fennig S., Kovasznay B., Rich C., Ram R., Pato C., Miller A.et al. Six-month stability of psychiatric diagnoses in first-admission patients with psychosis. American Journal of Psychiatry. 151:1994;1200-1208.
62. Fleiss J.L. Classification of the depressive disorders by numerical typology. Journal of Psychiatric Research. 9:1972;141-153.
63. Frangos E., Athanassenas G., Tsitourides S., Katsanou N., Alexandrakou P. Prevalence of DSM III schizophrenia among the first-degree relatives of schizophrenic probands. Acta Psychiatrica Scandinavica. 72:1985;382-386.
64. Geddes J.R., Lawrie S.M. Obstetric complications and schizophrenia: a meta-analysis. British Journal of Psychiatry. 167:1995;786-793.
65. Gerner R.H., Fairbanks L., Anderson G.M., Young J.G., Scheinin M., Linnoila M.et al. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. American Journal of Psychiatry. 141:1984;1533-1540.
66. Gershon E.S., DeLisi L.E., Hamovit J., Nurnberger J.I. Jr., Maxwell M.E., Schreiber J. A controlled family study of chronic psychoses. Schizophrenia and schizoaffective disorder. Archives of General Psychiatry. 45:1988;328-336.
67. Gershon E.S., Hamovit J., Guroff J.J., Dibble E., Leckman J.F., Sceery W. Jr.et al. A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands. Archives of General Psychiatry. 39:1982;1157-1167.
68. Ghaemi S.N. New treatments for bipolar disorder: the role of atypical neuroleptic agents. Journal of Clinical Psychiatry. 61:2000;33-42.
69. Gobert A., Rivet J.M., Lejeune F., Newman-Tancredi A., Adhumeau-Auclair A., Nicolas J.P.et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse. 36:2000;205-221.
70. Goldberg J.F., Harrow M., Leon A.C. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacology Bulletin. 32:1996;47-54.
71. Goodwin F.K., Post R.M., Dunner D.L., Gordon E.K. Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique. American Journal of Psychiatry. 130:1973;73-79.
72. Goodwin, F.R., Jamison, K. Biochemical and pharmacological studies. In: Manic-Depressive Illness. New York: Oxford; pp. 416-502.
73. Grossman L.S., Harrow M., Sands J.R. Features associated with thought disorder in manic patients at 2-4-year follow-up. American Journal of Psychiatry. 143:1986;306-311.
74. Gur R.E., Resnick S.M., Gur R.C., Alavi A., Caroff S., Kushner M.et al. Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography. Archives of General Psychiatry. 44:1987;126-129.
75. Guze S.B., Cloninger C.R., Martin R.L., Clayton P.J. A follow-up and family study of schizophrenia. Archives of General Psychiatry. 40:1983;1273-1276.
76. Hare E.H., Price J.S., Slater E. Mental disorder and season of birth. Nature. 241:1973;480.
77. Harrow M., Grossman L.S., Herbener E.S., Davies E.W. Ten-year outcome. patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms British Journal of Psychiatry. 177:2000;421-426.
78. Harvey I., Persaud R., Ron M.A., Baker G., Murray R.M. Volumetric MRI measurements in bipolars compared with schizophrenics and healthy controls. Psychological Medicine. 24:1994;689-699.
79. Hlastala S.A., Frank E., Mallinger A.G., Thase M.E., Ritenour A.M., Kupfer D.J. Bipolar depression. an underestimated treatment challenge Depression and Anxiety. 5:1997;73-83.
80. Hultman C.M., Sparen P., Takei N., Murray R.M., Cnattingius S. Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset. case-control study British Medical Journal. 318:1999;421-426.
81. Hunt N., Silverstone T. Tardive dyskinesia in bipolar affective disorder. a catchment area study International Clinical Psychopharmacology. 6:1991;45-50.
82. Jones P., Rodgers B., Murray R., Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 344:1994;1398-1402.
83. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A.et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry. 59:2002;530-537.
84. Kane J.M., Smith J.M. Tardive dyskinesia. prevalence and risk factors, 1959 to 1979 Archives of General Psychiatry. 39:1982;473-481.
85. Karlsson J.L. Inheritance of schizophrenia. Acta Psychiatrica Scandinavica Supplement. 247:1974;1-116.
86. Kasa K., Otsuki S., Yamamoto M., Sato M., Kuroda H., Ogawa N. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biological Psychiatry. 17:1982;877-883.
87. Keck P.E. Jr., Versiani M., Potkin S., West S.A., Giller E., Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. American Journal of Psychiatry. 160:2003;741-748.
88. Keck P.E., McElroy S.L., Strakowski S.M., Balistreri T.M., Kizer D.I., West S.A. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. Journal of Clinical Psychiatry. 57:1996;147-151.
89. Kendall R.E. The major functional psychoses: are they independent entities or part of a continuum? Philosophical and conceptual issues underlying the debate. Kerr A., McClelland H. Concepts of mental disorder. 1991;1-19 Gaskell, London.
90. Kendell R.E., Chalmers J.C., Platz C. Epidemiology of puerperal psychoses. British Journal of Psychiatry. 150:1987;662-673.
91. Kendell R.E., Gourlay J. The clinical distinction between psychotic and neurotic depressions. British Journal of Psychiatry. 117:1970;257-260.
92. Kendell R.E., Gourlay J. The clinical distinction between the affective psychoses and schizophrenia. British Journal of Psychiatry. 117:1970;261-626.
93. Kendler K.S., Gruenberg A.M., Tsuang M.T. Psychiatric illness in first-degree relatives of schizophrenic and surgical control patients. A family study using DSM-III criteria. Archives of General Psychiatry. 42:1985;770-779.
94. Kendler K.S., Karkowski L.M., Walsh D. The structure of psychosis. latent class analysis of probands from the Roscommon Family Study Archives of General Psychiatry. 55:1998;492-499.
95. Kendler K.S., McGuire M., Gruenberg A.M., O'Hare A., Spellman M., Walsh D. The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Archives of General Psychiatry. 50:1993;527-540.
96. Kendler K.S., McGuire M., Gruenberg A.M., O'Hare A., Spellman M., Walsh D. The Roscommon Family Study. IV. Affective illness, anxiety disorders, and alcoholism in relatives. Archives of General Psychiatry. 50:1993;952-960.
97. Kendler K.S., McGuire M., Gruenberg A.M., Walsh D. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study. American Journal of Psychiatry. 152:1995;755-764.
98. Ketter T.A., Calabrese J.R. Stabilization of mood from below versus above baseline in bipolar disorder. a new nomenclature Journal of Clinical Psychiatry. 63:2002;146-151.
99. Ketter T.A., Kimbrell T.A., George M.S., Dunn R.T., Speer A.M., Benson B.E.et al. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biological Psychiatry. 49:2001;97-109.
100. Ketter T.A., Kimbrell T.A., George M.S., Sachs N., Wang P.W., Post R.M. Predictors of treatment response in bipolar disorder. evidence from clinical and PET studies Journal of Clinical Psychiatry. 63:2002;21-25.
101. Ketter T.A., Wang P.W., Janenawasin S., Becker O.V., Wang A. The emerging role of olanzapine in bipolar disorders. Psychiatric Annals. 32:2002;753-762.
102. Kinney D.K., Yurgelun-Todd D.A., Tohen M., Tramer S. Pre- and perinatal complications and risk for bipolar disorder. a retrospective study Journal of Affective Disorders. 50:1998;117-124.
103. Korf J., van Praag H.M. Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism. a biochemical classification? Psychopharmacologia. 19:1971;148-152.
104. Koslow S.H., Maas J.W., Bowden C.L., Davis J.M., Hanin I., Javaid J. CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. Archives of General Psychiatry. 40:1983;999-1010.
105. Kraepelin E. Psychiatrie. Ein Lehrbuch für Studirende und Aerzte. 6th ed. 1899;J.A. Barth, Leipzig.
106. Kraepelin E. Die Erscheinungsformen des Irreseins. Zeitschrift für die gesamte Neurologie und Psychiatrie. 62:1920;1-29.
107. Lee A.S., Murray R.M. The long-term outcome of Maudsley depressives. British Journal of Psychiatry. 153:1988;741-751.
108. Lewis G., David A., Andreasson S., Allebeck P. Schizophrenia and city life. Lancet. 340:1992;137-140.
109. Lewis S.W., Murray R.M. Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. Journal of Psychiatric Research. 21:1987;413-421.
110. Lim K.O., Rosenbloom M.J., Faustman W.O., Sullivan E.V., Pfefferbaum A. Cortical gray matter deficit in patients with bipolar disorder. Schizophrenia Research. 40:1999;219-227.
111. Lish J.D., Dime-Meenan S., Whybrow P.C., Price R.A., Hirschfeld R.M. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. Journal of Affective Disorders. 31:1994;281-294.
112. Loranger A.W. Genetic independence of manic-depression and schizophrenia. Acta Psychiatrica Scandinavica. 63:1981;444-452.
113. Lucas G., De Deurwaerdere P., Caccia S., Umberto S. The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo. opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used Neuropharmacology. 39:2000;1053-1063.
114. Machon R.A., Mednick S.A., Huttunen M.O. Adult major affective disorder after prenatal exposure to an influenza epidemic. Archives of General Psychiatry. 54:1997;322-328.
115. MacQueen G.M., Young L.T., Robb J.C., Marriott M., Cooke R.G., Joffe R.T. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatrica Scandinavica. 101:2000;374-381.
116. Maier W., Lichtermann D., Minges J., Hallmayer J., Heun R., Benkert O., Levinson D.F. Continuity and discontinuity of affective disorders and schizophrenia. Results of a controlled family study. Archives of General Psychiatry. 50:1993;871-883.
117. Maj M. Clinical course and outcome of schizoaffective disorders. A three-year follow-up study. Acta Psychiatrica Scandinavica. 72:1985;542-550.
118. Marcelis M., Navarro-Mateu F., Murray R., Selten J.P., Van Os J. Urbanization and psychosis: a study of 1942-1978 birth cohorts in The Netherlands. Psychological Medicine. 28:1998;871-879.
119. Marcus R, Saha AR, Iwamoto T, Jody DN, Tourkodimitris S, Archibald DG et al. Aripiprazole versus placebo in acute mania, 42nd Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 10-13 2002.
120. Mason P., Harrison G., Croudace T., Glazebrook C., Medley I. The predictive validity of a diagnosis of schizophrenia. A report from the International Study of Schizophrenia (ISoS) coordinated by the World Health Organization and the Department of Psychiatry, University of Nottingham. British Journal of Psychiatry. 170:1997;321-327.
121. McGuffin P., Reveley A., Holland A. Identical triplets. non-identical psychosis? British Journal of Psychiatry. 140:1982;1-6.
122. Meltzer H.Y. Schizoaffective disorder. is the news of its nonexistence premature? Editor's introduction Schizophrenia Bulletin. 10:1984;11-13.
123. Mendlewicz J., Linkowski P., Wilmotte J. Relationship between schizoaffective illness and affective disorders or schizophrenia. Morbidity risk and genetic transmission. Journal of Affective Disorders. 2:1980;289-302.
124. Moldin S.O., Gottesman I.I., Erlenmeyer-Kimling L. Psychometric validation of psychiatric diagnoses in the New York High-Risk Study. Psychiatry Research. 22:1987;159-177.
125. Möller H.J., Bottlender R., Gross A., Hoff P., Wittmann J., Wegner U., Strauss A. The Kraepelinian dichotomy. preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms Schizophrenia Research. 56:2002;87-94.
126. Mukherjee S., Rosen A.M., Caracci G., Shukla S. Persistent tardive dyskinesia in bipolar patients. Archives of General Psychiatry. 43:1986;342-346.
127. Muller-Oerlinghausen B., Retzow A., Henn F.A., Giedke H., Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. Journal of Clinical Psychopharmacology. 20:2000;195-203.
128. Nasrallah H.A., Churchill C.M., Hamdan-Allan G.A. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. American Journal of Psychiatry. 145:1988;1455-1456.
129. Oreland L., Wiberg A., Asberg M., Traskman L., Sjostrand L., Thoren P., Bertilsson L., Tybring G. Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiatry Research. 4:1981;21-29.
130. Ösby U., Brandt L., Correia N., Ekbom A., Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Archives of General Psychiatry. 58:2001;844-850.
131. Ösby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research. 45:2000;21-28.
132. Papeschi R., McClure D.J. Homovanillic and 5-hydroxyindoleacetic acid in cerebrospinal fluid of depressed patients. Archives of General Psychiatry. 25:1971;354-358.
133. Pearlson G.D., Barta P.E., Powers R.E., Menon R.R., Richards S.S.et al. Ziskind-Somerfeld Research Award 1996. Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder. Biological Psychiatry. 41:1997;1-14.
134. 2 dopamine receptor density in psychotic and not nonpsychotic patients with bipolar disorder. Archives of General Psychiatry. 52:1995;471-477.
135. Pehek E.A., McFarlane H.G., Maguschak K., Price B., Pluto C.P. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Research. 888:2001;51-59.
136. Peselow E.D., Fieve R.R., Difiglia C., Sanfilipo M.P. Lithium prophylaxis of bipolar illness. The value of combination treatment. British Journal of Psychiatry. 164:1994;208-214.
137. Pickar D., Breier A., Hsiao J.K., Doran A.R., Wolkowitz O.M., Pato C.N. et al. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Archives of General Psychiatry. 47:1990;641-648.
138. Pope H.G. Jr., Lipinski J.F., Cohen B.M., Axelrod D.T. "Schizoaffective disorder": an invalid diagnosis? A comparison of schizoaffective disorder, schizophrenia, and affective disorder. American Journal of Psychiatry. 137:1980;921-927.
139. Pope H.G. Jr., Lipinski J.F. Jr. Diagnosis in schizophrenia and manic-depressive illness: a reassessment of the specificity of 'schizophrenic' symptoms in the light of current research. Archives of General Psychiatry. 35:1978;811-828.
140. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. American Journal of Psychiatry. 149:1992;999-1010.
141. Powell A., Thomson N., Hall D.J., Wilson L. Parent-child concordance with respect to sex and diagnosis in schizophrenia and manic-depressive psychosis. British Journal of Psychiatry. 123:1973;643-648.
142. Prien R.F., Caffey E.M. Jr., Klett C.J. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Archives of General Psychiatry. 26:1972;146-153.
143. Ragin A.B., Oltmanns T.F. Predictability as an index of impaired verbal communication in schizophrenic and affective disorders. British Journal of Psychiatry. 143:1983;578-583.
144. Rosen L.N., Rosenthal N.E., Van Dusen P.H., Dunner D.L., Fieve R.R. Age at onset and number of psychotic symptoms in bipolar I and schizoaffective disorder. American Journal of Psychiatry. 140:1983;1523-1524.
145. Rosenthal N.E., Rosenthal L.N., Stallone F., Dunner D.L., Fieve R.R. Toward the validation of RDC schizoaffective disorder. Archives of General Psychiatry. 37:1980;804-810.
146. Roy A., Pickar D., Linnoila M., Doran A.R., Ninan P., Paul S.M. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Research. 15:1985;281-292.
147. Sachs G.S. Use of clonazepam for bipolar affective disorder. Journal of Clinical Psychiatry. 51:1990;31-34. discussion, 50-53.
148. Sachs G.S., Grossman F., Ghaemi S.N., Okamoto A., Bowden C.L. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania. a double-blind, placebo-controlled comparison of efficacy and safety American Journal of Psychiatry. 159:2002;1146-1154.
149. Sachs G.S., Printz D.J., Kahn D.A., Carpenter D., Docherty J.P. The Expert Consensus Guideline Series. Medication Treatment of Bipolar Disorderser 2000 Postgraduate Medicine Spec. 2000;1-104.
150. Scharfetter C., Nusperli M. The group of schizophrenias, schizoaffective psychoses, and affective disorders. Schizophrenia Bulletin. 6:1980;586-591.
151. Sernyak M.J., Godleski L.S., Griffin R.A., Mazure C.M., Woods S.W. Chronic neuroleptic exposure in bipolar outpatients. Journal of Clinical Psychiatry. 58:1997;193-195.
152. Sernyak M.J., Griffin R.A., Johnson R.M., Pearsall H.R., Wexler B.E., Woods S.W. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. American Journal of Psychiatry. 151:1994;133-135.
153. Shenton M.E., Wible C.G., McCarley R.W. A review of magnetic resonance imaging studies of brain abnormalities in schizophrenia. Krishnan K.R.R., Doriaswamy P.M. Brain imaging in clinical psychiatry. 1997;297-380 Marcel Dekker, New York.
154. Smeraldi E., Negri F., Melica A.M. A genetic study of affective disorders. Acta Psychiatrica Scandinavica. 56:1977;382-398.
155. Soares J.C., Barwell M., Mallinger A.G., Kupfer D.J., Frank E. Adjunctive antipsychotic use in bipolar patients. an open 6-month prospective study following an acute episode Journal of Affective Disorders. 56:1999;1-8.
156. Soares J.C., Gershon S. The psychopharmacologic specificity of the lithium ion. origins and trajectory Journal of Clinical Psychiatry. 61:2000;16-22.
157. Strakowski S.M., Keck P.E. Jr., Sax K.W., McElroy S.L., Hawkins J.M. Twelve-month outcome of patients with DSM-III-R schizoaffective disorder: comparisons to matched patients with bipolar disorder. Schizophrenia Research. 35:1999;167-174.
158. Strik W.K., La Malfa G., Cabras P. A bidimensional model for diagnosis and classification of functional psychoses. Comprehensive Psychiatry. 30:1989;313-319.
159. Subrahmanyam S. Role of biogenic amines in certain pathological conditions. Brain Research. 87:1975;355-362.
160. Swann A.C., Janicak P.L., Calabrese J.R., Bowden C.L., Dilsaver S.C., Morris D.D.et al. Structure of mania. depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants Journal of Affective Disorders. 67:2001;123-132.
161. Takahashi S., Yamane H., Kondo H., Tani N., Kato N. CSF monoamine metabolites in alcoholism. a comparative study with depression Folia Psychiatria et Neurologia Japan. 28:1974;347-354.
162. Taylor M.A. Are schizophrenia and affective disorder related? A selective literature review. American Journal of Psychiatry. 149:1992;22-32.
163. Tohen M., Baker R.W., Altshuler L.L., Zarate C.A., Suppes T., Ketter T.A.et al. Olanzapine versus divalproex in the treatment of acute mania. American Journal of Psychiatry. 159:2002;1011-1017.
164. Tohen M., Chengappa K.N., Suppes T., Zarate C.A. Jr., Calabrese J.R., Bowden C.L.etal. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Archives of General Psychiatry. 59:2002;62-69.
165. Tohen M., Jacobs T.G., Grundy S.L., McElroy S.L., Banov M.C., Janicak P.G.et al. Efficacy of olanzapine in acute bipolar mania. a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group Archives of General Psychiatry. 57:2000;841-849.
166. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. American Journal of Psychiatry 2003 160; 1263-71.
167. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N., Daniel D.G.et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. American Journal of Psychiatry. 156:1999;702-709.
168. Tohen M., Strakowski S.M., Zarate C. Jr., Hennen J., Stoll A.L., Suppes T.et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biological Psychiatry. 48:2000;467-476.
169. Tohen M., Tsuang M.T., Goodwin D.C. Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. American Journal of Psychiatry. 149:1992;1580-1584.
170. Tohen, M., Vieta, E., Calabrese, J., Ketter, T., Sachs, G., Bowden, C. et al. Efficacy of olanzapine and olanzapine/fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry (in press).
171. Tohen M., Waternaux C.M., Tsuang M.T. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Archives of General Psychiatry. 47:1990;1106-1111.
172. Tohen M., Waternaux C.M., Tsuang M.T., Hunt A.T. Four-year follow-up of twenty-four first-episode manic patients. Journal of Affective Disorders. 19:1990;79-86.
173. Traskman L., Asberg M., Bertilsson L., Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Archives of General Psychiatry. 38:1981;631-636.
174. Tsuang M.T., Dempsey G.M. Long-term outcome of major psychoses. II. Schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group. Archives of General Psychiatry. 36:1979;1302-1304.
175. Tsuang M.T., Kendler K.K., Gruenberg A.M. DSM-III schizophrenia. is there evidence for familial transmission Acta Psychiatrica Scandinavica Supplement. 319:1985;77-83.
176. Tsuang M.T., Simpson J.C. Schizoaffective disorder. concept and reality Schizophrenia Bulletin. 10:1984;14-25.
177. Tsuang M.T., Winokur G., Crowe R.R. Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression and surgical conditions. British Journal of Psychiatry. 137:1980;497-504.
178. Tsuang M.T., Woolson R.F., Fleming J.A. Long-term outcome of major psychoses. I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Archives of General Psychiatry. 36:1979;1295-1301.
179. Valles V., Van Os J., Guillamat R., Gutierrez B., Campillo M., Gento P. et al. Increased morbid risk for schizophrenia in families of in-patients with bipolar illness. Schizophrenia Research. 42:2000;83-90.
180. van Os J., Jones P., Lewis G., Wadsworth M., Murray R. Developmental precursors of affective illness in a general population birth cohort. Archives of General Psychiatry. 54:1997;625-631.
181. Van Os J., Jones P., Sham P., Bebbington P., Murray R.M. Risk factors for onset and persistence of psychosis. Social Psychiatry and Psychiatric Epidemiology. 33:1998;596-605.
182. van Praag H.M., Korf J., Schut D. Cerebral monoamines and depression. An investigation with the Probenecid technique. Archives of General Psychiatry. 28:1973;827-831.
183. Verdoux H., Gonzales B., Takei N., Bourgeois M. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. Journal of Affective Disorders. 38:1996;81-87.
184. Vestergaard P., Sorensen T., Hoppe E., Rafaelsen O.J., Yates C.M., Nicolaou N. Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatrica Scandinavica. 58:1978;88-96.
185. Videbech P. MRI findings in patients with affective disorder. a meta-analysis Acta Psychiatrica Scandinavica. 96:1997;157-168.
186. Videbech P., Gouliaev G. First admission with puerperal psychosis. 7-14 years of follow-up Acta Psychiatrica Scandinavica. 91:1995;167-173.
187. Waddington J.L., Brown K., O'Neill J., McKeon P., Kinsella A. Cognitive impairment, clinical course and treatment history in out-patients with bipolar affective disorder. relationship to tardive dyskinesia Psychological Medicine. 19:1989;897-902.
188. Waldmeier P.C. Is there a common denominator for the antimanic effect of lithium and anticonvulsants? Pharmacopsychiatry. 20:1987;37-47.
189. Wang P.W., Ketter T.A. Biology and recent brain imaging studies in affective psychoses. Current Psychiatry Reports. 2:2000;298-304.
190. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Archives of General Psychiatry. 43:1986;114-124.
191. Weissman M.M., Gershon E.S., Kidd K.K., Prusoff B.A., Leckman J.F., Dibble E.et al. Psychiatric disorders in the relatives of probands with affective disorders. The Yale University-National Institute of Mental Health Collaborative Study. Archives of General Psychiatry. 41:1984;13-21.
192. Welner A., Welner Z., Leonard M.A. Bipolar manic-depressive disorder. a reassessment of course and outcome Comprehensive Psychiatry. 18:1977;327-332.
193. Widerlov E., Bissette G., Nemeroff C.B. Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients. Journal of Affective Disorders. 14:1988;99-107.
194. Wildenauer D.B., Schwab S.G., Maier W., Detera-Wadleigh S.D. Do schizophrenia and affective disorder share susceptibility genes? Schizophrenia Research. 39:1999;107-111.
195. Wilk S., Shopsin B., Gershon S., Suhl M. Cerebrospinal fluid levels of MHPG in affective disorders. Nature. 235:1972;440-441.
196. Winokur G., Clayton P.J., Reich T. Manic Depressive Illness. 1969;C.V. Mosby, Saint Louis.
197. Winsberg M.E., Sachs N., Tate D.L., Adalsteinsson E., Spielman D., Ketter T.A. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biological Psychiatry. 47:2000;475-481.
198. Yatham, L. N. (2000). Safety and efficacy of risperidone as combination therapy for the manic phase of bipolar disorder: preliminary findings of a randomized, double-blind study (RIS-INT-46), 22nd Congress of Collegium Internationale Neuro-Psychopharmacologicum. Brussels, July 9-13, 2000.
199. Yurgelun-Todd D.A., Waternaux C.M., Cohen B.M., Gruber S.A., English C.D., Renshaw P.F. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. American Journal of Psychiatry. 153:1996;200-205.
200. Zajecka J.M., Weisler R., Sachs G., Swann A.C., Wozniak P., Sommerville K.W. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. Journal of Clinical Psychiatry. 63:2002;1148-1155.
201. Zarate C.A. Jr., Tohen M. Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. Journal of Clinical Psychiatry. 61:2000;33-38.